iron

all catalysts(1)

News(10)

• Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
  The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
  biospace · 7d ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 8d ago
• Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
  Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.
  biospace · 9d ago
• After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
  With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
  fiercebiotech · 9d ago
• Silence brings the noise to Takeda with phase 2 blood cancer win
  A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…
  fiercebiotech · 11d ago
• Syphilis spreads while researchers contend with federal constraints and a drug shortage
  At the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage.
  stat · 20d ago
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 22d ago
• ‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
  Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.
  fiercebiotech · 22d ago
• After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
  Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.
  stat · 23d ago
• Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency
  “Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write CHOP’s J. Todd R. Lawrence and Madison A. Kesler.
  stat · 24d ago